TESARO Inc

Type: Company
Name: TESARO Inc
Nationalitet: United States
Webbadress: http://tesarobio.com/
Publicerad 23 hours ago - uppdaterad 17 hours ago - 2 rapporter

Business Digest for Sept. 16, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW.Waltham's Tesaro submits rolapitant applicationTesaro Inc., a Waltham-based oncology-focused biopharmaceutical company, this week announced that it has submitted the new drug application ... [Published Wicked Local Ashland - 17 hours ago]
Publicerad Sep 15 2014 - uppdaterad Sep 15 2014 - 1 rapporter

East Coast Biotech Roundup: Maraganore, Flex, NPS, Retrophin, & More

It’s back to work, back to school, and back to the grind in biotech. One local company inched towards a potential FDA approval, yet its stock is down more than 10 percent. Another biotech came under fire for a big price hike on an old drug. And a new ... [Published Xconomy - Sep 15 2014]
Publicerad Sep 11 2014 - uppdaterad Sep 11 2014 - 1 rapporter

AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer

The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in ... [Published BioPortfolio - Sep 11 2014]
Publicerad Sep 11 2014 - uppdaterad Sep 11 2014 - 2 rapporter

Opko Health: Licensee Tesaro Submits NDA for Rolapitant to Prevent CINV

Opko Health reported that its licensee, Tesaro has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational neurokinin-1 (NK-1) receptor antagonist in development for the ... [Published Individual.com - Sep 11 2014]
Publicerad Sep 10 2014 - uppdaterad Sep 10 2014 - 1 rapporter

TESARO submits NDA for chemotherapy-induced nausea and vomiting drug to FDA

OPKO Health, Inc., a biopharmaceutical and diagnostics company, has announced that its licensee, TESARO, Inc. a biopharmaceutical company, has submitted a new drug application, or NDA, to the FDA for approval of oral rolapitant, an investigational neurokinin-1 ... [Published Individual.com - Sep 10 2014]
Publicerad Sep 08 2014 - uppdaterad Sep 09 2014 - 11 rapporter

Tesaro seeks US FDA approval for rolapitant for prevention of CINV

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, announced that its licensee, Tesaro, Inc. has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of oral rolapitant, an investigational ... [Published PharmaBiz - Sep 09 2014]
Publicerad Aug 23 2014 - uppdaterad Aug 23 2014 - 1 rapporter

Business Digest for Aug. 23, 2014

Follow Daily News Business Editor Bob Tremblay on Twitter @Bob Tremblay_MW. Body Uniqlo to open stores in Natick, Chestnut Hill Uniqlo, the Japanese casual wear designer, manufacturer and retailer, opens its first two permanent stores in Massachusetts ... [Published MetroWest Daily News - Aug 23 2014]
Publicerad Aug 22 2014 - uppdaterad Aug 22 2014 - 1 rapporter

Tekmira Up On Positive Ebola-Related Drug Study; Philips Receives FDA 510(k) Clearance For TAVI

Below is a look at some of the headlines for companies that made news in the healthcare sector on August 21, 2014.Tekmira Pharmaceuticals (NASDAQ: TKMR) shares gained more than four percent after it was reported that one of its drugs showed promising ... [Published BioMedReports - Aug 22 2014]
Publicerad Aug 21 2014 - uppdaterad Aug 21 2014 - 1 rapporter

TESARO : Paradigm Announces Molecular Profiling Collaboration with TESARO

Paradigm will use its advanced molecular capabilities to characterize patient tissue samples from clinical trials to better predict which patients may be sensitive or resistant to TESARO's TSR-011.This may lead to more successful clinical trial outcomes ... [Published 4 Traders - Aug 21 2014]
Publicerad Aug 21 2014 - uppdaterad Aug 21 2014 - 4 rapporter

TESARO Announces Participation at Several Upcoming Investor Conferences

WALTHAM, Mass., Aug. 21, 2014 (GLOBE NEWSWIRE) -- TESAROAbout TESAROTESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. ... [Published BusinessWeek - Aug 21 2014]
Publicerad Aug 20 2014 - uppdaterad Aug 21 2014 - 3 rapporter

Paradigm collaborates with TESARO on molecular profiling

Paradigm today announced a collaboration with TESARO. ... [Published PBR - News - Aug 21 2014]
Publicerad May 12 2014 - uppdaterad May 13 2014 - 2 rapporter

Why Tesaro (TSRO) Stock Is Surging Today

NEW YORK (TheStreet) -- Tesaro  surged Monday after the biopharmaceutical company announced positive top-line results from the third and final Phase 3 trial of rolapitant, an investigational neurokinin-1, or NK-1, receptor antagonist in development for ... [Published The Street Latest - May 12 2014]

Citat

Original Article: NEXT ARTICLE More From BioPortfolio on "AstraZeneca is developing new PARP inhibitor for treatment of ovarian cancer"
"We are pleased by the very professional work of the Tesaro team in completing the studies required to file the NDA. Opko's other internal projects are progressing as planned and we are anxious to introduce these important new products to the market as rapidly as possible" said Phillip Frost, M D , Chairman and Chief Executive Officer of Opko
...for certain autoimmune disorders," said Ganesh Kaundinya, Ph D , Chief Scientific Officer of Momenta PharmaceuticalsMomenta Pharmaceuticals Inc. "The target for the antibodies was selected based on Momenta's research of the complex biology underlying the anti-inflammatory effects of IVIg.  As a result of this research, we engaged AnaptysBio to engineer a novel recombinant antibody that targets a specific biological pathway we believe is important for autoimmune diseases.  We look forward to sharing more details of this program and our other lead programs in the autoimmune disease area at our R&D day in October."
...the oral rolapitant NDA submission represents a significant milestone for the Company," said Mary Lynne Hedley, Ph D , President and COO of TESARO. "We believe rolapitant could become an important new treatment for the prevention of nausea and vomiting for patients undergoing emetogenic chemotherapy."

Mer innehåll

Alla (79) | Nyheter (48) | Rapporter (0) | Bloggar (14) | Ljud/Video (0) | Faktablad (0) | Pressreleaser (16)
sort by: Date | Relevance
Business Digest for Sept. 16, 2014 [Published Wicked Local Ashland - 17 hours ago]
Business Digest for Sept. 16, 2014 [Published MetroWest Daily News - 23 hours ago]
East Coast Biotech Roundup: Maraganore, Flex, N... [Published Xconomy - Sep 15 2014]
AstraZeneca is developing new PARP inhibitor fo... [Published BioPortfolio - Sep 11 2014]
Opko Health: Licensee Tesaro Submits NDA for Ro... [Published Individual.com - Sep 11 2014]
Tesaro Turns in New Drug Application for Rolapi... [Published Individual.com - Sep 11 2014]
TESARO submits NDA for chemotherapy-induced nau... [Published Individual.com - Sep 10 2014]
Nausea and Vomiting Treatment Rolapitant Submit... [Published PT Community - Sep 09 2014]
TESARO Announces Submission of Rolapitant New D... [Published Pappas Ventures - Sep 09 2014]
TESARO Seeks FDA Approval for NK-1 Receptor Rol... [Published Zacks.com - Sep 09 2014]
Rolapitant Submitted for Approval for Preventio... [Published Chemotherapy Advisor - Sep 09 2014]
Tesaro seeks US FDA approval for rolapitant for... [Published PharmaBiz - Sep 09 2014]
EBS Gets Funded, HPTX Pulls Plug On Diabetes Dr... [Published RTTNews.com - Sep 09 2014]
Opko Health, Inc. Licensee Tesaro, Inc. Submits... [Published BioSpace - Sep 08 2014]
Sector Update: Health Care Stocks End Mixed; Op... [Published Nasdaq - Sep 08 2014]
OPKO Licensee TESARO Submits NDA For Rolapitant [Published RTTNews.com - Sep 08 2014]
OPKO Licensee TESARO Submits New Drug Applicati... [Published CNBC - Sep 08 2014]
OPKO Licensee TESARO Submits New Drug Applicati... [Published Business Wire Health News - Sep 08 2014]
TESARO Inc announces submission of rolapitant n... [Published Reuters - Sep 08 2014]
Momenta Pharmaceuticals Exercises Option to Acq... [Published Indianapolis Business Journal - Sep 08 2014]
TESARO Announces Submission of Rolapitant New D... [Published GlobeNewswire: Advertising News - Sep 08 2014]
TESARO Reports NDA Submission Of Rolapitant To ... [Published RTTNews.com - Sep 08 2014]
TESARO Announces Submission of Rolapitant New D... [Published Wall Street Select - Sep 08 2014]
TESARO Announces Submission Of Rolapitant New D... [Published Benzinga.com - Sep 08 2014]
TESARO Announces Submission of Rolapitant New D... [Published BusinessWeek - Sep 08 2014]
Best Way to Treat Mediastinal Lymphomas Is Stil... [Published The ASCO Post - Sep 02 2014]
Business Digest for Aug. 23, 2014 [Published MetroWest Daily News - Aug 23 2014]
Competition And Momentum Weighing On Clovis Onc... [Published Seeking Alpha - Aug 23 2014]
Tekmira Up On Positive Ebola-Related Drug Study... [Published BioMedReports - Aug 22 2014]
TESARO : Paradigm Announces Molecular Profiling... [Published 4 Traders - Aug 21 2014]
1 2 3
I fokus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Nyhetsvolym
Document Volume
Nätverk
Network

Bloggar

sort by: Date | Relevance
OPKO Licensee TESARO Submits New Drug Applicati... [Published Business Wire Health News - Sep 08 2014]
Paradigm collaborates with TESARO on molecular ... [Published PBR - News - Aug 21 2014]
Paradigm Announces Molecular Profiling Collabor... [Published PR Newswire: Health - Aug 20 2014]
Boston CEO Conference to Feature CEOs of Aegeri... [Published Business Wire Health News - May 20 2014]
Clinical Trial Updates, Leadership Appointments... [Published PR Newswire: Financial Services - May 15 2014]
1 2 3

Pressreleaser

sort by: Date | Relevance
TESARO Announces Submission of Rolapitant New D... [Published GlobeNewswire: Advertising News - Sep 08 2014]
TESARO Announces Participation at Several Upcom... [Published GlobeNewswire: Acquisitions News - Aug 21 2014]
TESARO Announces Second-Quarter 2014 Operating ... [Published GlobeNewswire: Advertising News - Jul 24 2014]
TESARO to Announce Second-Quarter 2014 Financia... [Published GlobeNewswire: Advertising News - Jul 10 2014]
Market Expansion, Merger Agreements, Management... [Published Financial Services - Jul 02 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.